ANI Pharmaceuticals (NASDAQ:ANIP) Rating Lowered to Hold at StockNews.com

StockNews.com cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a report published on Saturday morning.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a buy rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Wednesday, August 7th. Truist Financial downgraded shares of ANI Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $82.75.

ANI Pharmaceuticals Trading Down 3.4 %

Shares of ANIP stock opened at $58.48 on Friday. The stock has a market capitalization of $1.23 billion, a P/E ratio of 36.55 and a beta of 0.71. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The company has a 50 day moving average price of $61.82 and a 200 day moving average price of $64.04.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.06 earnings per share. Equities research analysts predict that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the sale, the senior vice president now owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,007 shares of company stock valued at $4,091,535. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of ANIP. Texas Permanent School Fund Corp grew its position in ANI Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after buying an additional 172 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after acquiring an additional 200 shares in the last quarter. Arizona State Retirement System increased its stake in shares of ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 211 shares during the period. Simplicity Wealth LLC increased its stake in shares of ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after acquiring an additional 227 shares during the period. Finally, California State Teachers Retirement System lifted its position in ANI Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 233 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.